Novel immunotherapies based on activators of the STING pathways or other endogenous IFN related signals (extensively discussed in other reviews [2,13]) are in an early phase of clinical experimentation and may represent a highly valuable approach for a localized activation of the endogenous IFN-I system to be exploited in cancer therapy. This evidence concerns the gene STING1 and cancer.